BJUI Compass (Jun 2024)
CEA (CEACAM5) expression is common in muscle‐invasive urothelial carcinoma of the bladder but unrelated to the disease course
- Henning Plage,
- Kira Furlano,
- Jörg Neymeyer,
- Sarah Weinberger,
- Benedikt Gerdes,
- Mandy Hubatsch,
- Bernhard Ralla,
- Antonia Franz,
- Annika Fendler,
- Michela deMartino,
- Florian Roßner,
- Simon Schallenberg,
- Sefer Elezkurtaj,
- Martina Kluth,
- Maximilian Lennartz,
- Niclas C. Blessin,
- Andreas H. Marx,
- Henrik Samtleben,
- Margit Fisch,
- Michael Rink,
- Krystian Kaczmarek,
- Thorsten Ecke,
- Steffen Hallmann,
- Stefan Koch,
- Nico Adamini,
- Sarah Minner,
- Ronald Simon,
- Guido Sauter,
- Joachim Weischenfeldt,
- Tobias Klatte,
- Thorsten Schlomm,
- David Horst,
- Henrik Zecha,
- Marcin Slojewski
Affiliations
- Henning Plage
- Department of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- Kira Furlano
- Department of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- Jörg Neymeyer
- Department of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- Sarah Weinberger
- Department of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- Benedikt Gerdes
- Department of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- Mandy Hubatsch
- Department of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- Bernhard Ralla
- Department of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- Antonia Franz
- Department of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- Annika Fendler
- Department of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- Michela deMartino
- Department of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- Florian Roßner
- Institute of Pathology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- Simon Schallenberg
- Institute of Pathology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- Sefer Elezkurtaj
- Institute of Pathology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- Martina Kluth
- Institute of Pathology University Medical Center Hamburg‐Eppendorf Hamburg Germany
- Maximilian Lennartz
- Institute of Pathology University Medical Center Hamburg‐Eppendorf Hamburg Germany
- Niclas C. Blessin
- Institute of Pathology University Medical Center Hamburg‐Eppendorf Hamburg Germany
- Andreas H. Marx
- Department of Pathology Academic Hospital Fuerth Fuerth Germany
- Henrik Samtleben
- Department of Pathology Academic Hospital Fuerth Fuerth Germany
- Margit Fisch
- Department of Urology University Medical Center Hamburg‐Eppendorf Hamburg Germany
- Michael Rink
- Department of Urology Marienhospital Hamburg Hamburg Germany
- Krystian Kaczmarek
- Department of Urology and Urological Oncology Pomeranian Medical University Szczecin Poland
- Thorsten Ecke
- Department of Urology Helios Hospital Bad Saarow Bad Saarow Germany
- Steffen Hallmann
- Department of Urology Helios Hospital Bad Saarow Bad Saarow Germany
- Stefan Koch
- Department of Pathology Helios Hospital Bad Saarow Bad Saarow Germany
- Nico Adamini
- Department of Urology Albertinen Hospital Hamburg Germany
- Sarah Minner
- Institute of Pathology University Medical Center Hamburg‐Eppendorf Hamburg Germany
- Ronald Simon
- Institute of Pathology University Medical Center Hamburg‐Eppendorf Hamburg Germany
- Guido Sauter
- Institute of Pathology University Medical Center Hamburg‐Eppendorf Hamburg Germany
- Joachim Weischenfeldt
- Department of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- Tobias Klatte
- Department of Urology Helios Hospital Bad Saarow Bad Saarow Germany
- Thorsten Schlomm
- Department of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- David Horst
- Institute of Pathology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- Henrik Zecha
- Department of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
- Marcin Slojewski
- Department of Urology and Urological Oncology Pomeranian Medical University Szczecin Poland
- DOI
- https://doi.org/10.1002/bco2.354
- Journal volume & issue
-
Vol. 5,
no. 6
pp. 699 – 706
Abstract
Abstract Objectives Carcinoembryonic antigen (CEA) is a cell surface glycoprotein that represents a promising therapeutic target. Serum measurement of shedded CEA can be utilized for monitoring of cancer patients. Material and Methods To evaluate the potential clinical significance of CEA expression in urothelial bladder neoplasms, CEA was analysed by immunohistochemistry in more than 2500 urothelial bladder carcinomas in a tissue microarray format. Results CEA staining was largely absent in normal urothelial cells but was observed in 30.4% of urothelial bladder carcinomas including 406 (16.7%) with weak, 140 (5.8%) with moderate, and 192 (7.9%) with strong staining. CEA positivity occurred in 10.9% of 411 pTaG2 low‐grade, 32.0% of 178 pTaG2 high‐grade, and 43.0% of 93 pTaG3 tumours (p 0.25). Conclusion CEA increases markedly with grade progression in pTa tumours, and expression occurs in a significant fraction of pT2–4 urothelial bladder carcinomas. The high rate of CEA positivity in pT2–4 carcinomas offers the opportunity of using CEA serum measurement for monitoring the clinical course of these cancers. Moreover, CEA positive urothelial carcinomas are candidates for a treatment by targeted anti‐CEA drugs.
Keywords
